An annual oral glucose tolerance test (OGTT) has become part of standard care in cystic fibrosis (CF) to screen for CF-related diabetes (CFRD) in patients older than 10 years of age ([@B1]). Up to 15% of patients with CF develop hypoglycemia during an OGTT ([@B2]), and there is some discussion whether such a response indicates an increased risk for the development of CFRD. In fact, a reactive hypoglycemia has been considered as an early stage of CFRD ([@B3]). However, the prognostic value of such a reactive hypoglycemia with respect to future glucose control has never been studied. Based on a delayed insulin secretion in CF, which might be relevant to both a hypoglycemic as well as a hyperglycemic response to a glucose challenge ([@B4]), we hypothesized that the hypoglycemic response to a glucose challenge could indicate a stage preceding CFRD*.* The objective of this study therefore was to determine the prognostic value of a hypoglycemic response during an OGTT for future impaired glucose tolerance (IGT) and CFRD.

We retrospectively analyzed data collected between 2001 and 2009 from 1,779 patients who participated in a longitudinal prospective study on "Early Diagnosis of Diabetes Mellitus in Patients with Cystic Fibrosis." All patients were 10 years of age or older and performed standardized OGTTs ([@B5]), at least on an annual basis. OGTT results were categorized following the World Health Organization guidelines ([@B5]). All patients included into the current analysis (*n* = 841) had at least two valid OGTTs each and a normal glucose tolerance to the first challenge. The patients with normal glucose tolerance were divided into two subgroups: one group with an entirely normal, nonhypoglycemic plasma glucose level 2 h after the challenge (3.3--7.7 mmol/L; 60--139 mg/dL) and one group with a hypoglycemic 2-h plasma glucose level (\<3.3 mmol/L; \<60 mg/dL). The groups were compared regarding the incidence of IGT and CFRD at the last available OGTT using χ^2^ statistics. A hypoglycemic response to the first oral glucose challenge was observed in 53 of the 841 participants (6.3%). There was no difference between patients with an entirely normal, nonhypoglycemic response (*n* = 788) and those with a hypoglycemic response to the first OGTT in the incidence of CFRD (10.3 vs. 13.2%) or IGT (12.9 vs. 11.3%) at the last OGTT 3.5 ± 1.8 years later. Likewise, groups did not differ in age, sex distribution, BMI, and time interval between first and last OGTT.

The 7% incidence of hypoglycemia observed in our study was lower than the 15% previously reported for CF patients ([@B2]). A hypoglycemic response to an OGTT does not indicate a risk for future CFRD or IGT, at least not in the following 3.5 years. This finding is in contrast to our hypothesis. We had expected that a dysregulation of insulin secretion in CF would be responsible for reactive hypoglycemia and also---at least in part---for glucose intolerance and overt diabetes in this disease. Our data indicate that the mechanisms underlying reactive hypoglycemia are different from those involved in glucose intolerance or CFRD in CF.
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